N. Anthony Coles
2021 - Cerevel Therapeutics Holdings
In 2021, N. Anthony Coles earned a total compensation of $8.1M as Chairperson and Chief Executive Officer at Cerevel Therapeutics Holdings, a 196% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $390,635 |
|---|---|
| Option Awards | $7,099,999 |
| Salary | $617,701 |
| Total | $8,108,335 |
Coles received $7.1M in option awards, accounting for 88% of the total pay in 2021.
Coles also received $390.6K in non-equity incentive plan and $617.7K in salary.
Rankings
In 2021, N. Anthony Coles' compensation ranked 1,427th out of 12,415 executives tracked by ExecPay. In other words, Coles earned more than 88.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,427 out of 12,415 | 89th |
Division Manufacturing | 513 out of 5,505 | 91st |
Major group Chemicals And Allied Products | 189 out of 2,375 | 92nd |
Industry group Drugs | 158 out of 2,096 | 93rd |
Industry Pharmaceutical Preparations | 107 out of 1,546 | 93rd |
Source: SEC filing on April 28, 2022.
Coles' colleagues
We found five more compensation records of executives who worked with N. Anthony Coles at Cerevel Therapeutics Holdings in 2021.
2021
Abraham Ceesay
Cerevel Therapeutics Holdings
President
2021
Kathy Yi
Cerevel Therapeutics Holdings
Chief Financial Officer
2021
Raymond Sanchez
Cerevel Therapeutics Holdings
Chief Medical Officer
2021
Scott Akamine
Cerevel Therapeutics Holdings
Chief Legal Officer
2021
Mark Bodenrader
Cerevel Therapeutics Holdings
Chief Financial Officer
News
Cerevel Therapeutics Holdings CEO N Coles' 2021 pay jumps 990% to $8.1M
April 28, 2022
KINETA CEO Richard MDPhD receives $4.5M in 2021
April 25, 2022
Cerevel Therapeutics Holdings Chief Corporate Affairs Officer Kathleen MA receives $3.7M in 2020
April 28, 2021
KINETA CEO Meenu Chhabra's 2020 pay jumps 65% to $3.3M
April 22, 2021